Tripos Names New VP of Marketing and Corporate Development, Discovery Informatics
News Dec 16, 2005
Tripos, Inc. has announced that it has appointed Kathleen Mensler as vice president of marketing and corporate development, Discovery Informatics.
In this role, Mensler will oversee worldwide marketing, manage existing alliances, seek new business relationships and contribute to the strategic direction for the growth and expansion of Tripos’ Discovery Informatics business.
"Kathleen is an experienced leader who holds a strong performance record in helping grow products and expand companies in the life science industry," said Bryan Koontz, senior vice president and general manager of Discovery Informatics at Tripos.
"Her deep knowledge of business, science and informatics, combined with her intuitive understanding of customer needs, will be a tremendous asset to Tripos."
Mensler brings 20 years of business and marketing experience in life science informatics to Tripos.
Most recently, she served as vice president of business development at Elsevier MDL.
She has also held executive-level positions in marketing, product development and business management at MDL, and established its consulting and customer service organizations. Before her tenure at MDL, Mensler worked as a medicinal chemist at Merck, Inc.
"Throughout its history, Tripos has been an innovator in chemical informatics," Mensler said.
"Now the company is poised to have even greater impact on its customers’ discovery science and processes."
"I am excited to join the Tripos team and look forward to contributing to a new era at Tripos."
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE